home >
articles >
parkinson's disease > randomized, double-blind, pilot evaluation of
intravenous glutathione in Parkinson's disease
Glutathione Articles - Parkinson's Disease
Randomized, double-blind, pilot evaluation of intravenous glutathione in
Parkinson's disease
Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D
Mov Disord. 2009 Feb 19. [Epub ahead of print]
> download abstract
as a PDF
ABSTRACT
The objective of this study was to evaluate the safety, tolerability,
and preliminary efficacy of intravenous glutathione in Parkinson's disease
(PD) patients. This was a randomized, placebo-controlled, double-blind,
pilot trial in subjects with PD whose motor symptoms were not adequately
controlled with their current medication regimen. Subjects were randomly
assigned to receive intravenous glutathione 1,400 mg or placebo administered
three times a week for 4 weeks. Twenty-one subjects were randomly assigned,
11 to glutathione and 10 to placebo. One subject who was assigned to
glutathione withdrew from the study for personal reasons prior to undergoing
any post-randomization efficacy assessments. Glutathione was well tolerated
and there were no withdrawals because of adverse events in either group.
Reported adverse events were similar in the two groups. There were no
significant differences in changes in Unified Parkinson's Disease Rating
Scale (UPDRS) scores. Over the 4 weeks of study medication administration,
UPDRS ADL + motor scores improved by a mean of 2.8 units more in the
glutathione group (P = 0.32), and over the subsequent 8 weeks worsened by a
mean of 3.5 units more in the glutathione group (P = 0.54). Glutathione was
well tolerated and no safety concerns were identified. Preliminary efficacy
data suggest the possibility of a mild symptomatic effect, but this remains
to be evaluated in a larger study. (c) 2009 Movement Disorder Society.
Glutathione Experts | What is Glutathione (GSH)?
| Glutathione Articles |
GSH FAQs
| GSH & Diseases |
Contact
